GlassScriptPhysician profile
Hitesh Kaul
NPI 1437105756
$1,539.73
in general payments reported to CMS, 2019-2025
9 companies · $804 in 2025
The $804 reported for 2025 was more than what a typical Transplant Surgery provider received nationally (typical 2025 total: $423).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34.32 · 2020: $113 · 2021: $175 · 2022: $68.38 · 2023: $225 · 2024: $120 · 2025: $804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $749 · Food and Beverage: $400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $749.10 |
| Food and Beverage | $399.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organox LTD | $803.70 | 2025 | |
| Integra Lifesciences Corporation | $428.28 | 2021-2023 | Integra, Integra Dermal Regeneration Template, Omnigraft |
| Sanofi-Aventis U.S. LLC | $119.56 | 2024 | |
| Ethicon US, LLC | $68.42 | 2020 | |
| Veloxis Pharmaceuticals, INC. | $39.10 | 2019-2023 | Envarsus |
| Oxford Immunotec USA INC | $25.46 | 2020 | |
| Abbvie INC. | $19.08 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $18.41 | 2023 | Livtencity |
| Genzyme Corporation | $17.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hitesh Kaul listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.